Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

umite: fast quantification of Smart-seq3 libraries with improved UMI retrieval.

Bioinformatics (Oxford, England)·2026
Same author

Unlocking the full potential of nanopore sequencing: tips, tricks, and advanced data analysis techniques.

Nucleic acids research·2026
Same author

The regulatory code of injury-responsive enhancers enables precision cell-state targeting in the CNS.

Nature neuroscience·2025
Same author

Author Correction: Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression.

Nature communications·2025
Same author

Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression.

Nature communications·2025
Same author

Unraveling regulatory feedback mechanisms in adult neurogenesis through mathematical modelling.

NPJ systems biology and applications·2025

Related Experiment Video

Updated: May 12, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

CD95 in cancer: tool or target?

Ana Martin-Villalba1, Enric Llorens-Bobadilla, Damian Wollny

  • 1Molecular Neurobiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. a.martin-villalba@dkfz.de

Trends in Molecular Medicine
|April 2, 2013
PubMed
Summary

The CD95 receptor

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • The CD95 (Fas/Apo1) receptor's role in cancer has been debated for over 30 years.
  • Initially recognized for inducing apoptosis, CD95 was considered a potential anticancer therapy.
  • Emerging evidence highlights CD95's involvement in nonapoptotic pathways promoting tumorigenesis.

Purpose of the Study:

  • To review the dual role of CD95 signaling in cancer.
  • To discuss the implications of CD95's pro-tumorigenic functions for cancer therapy.
  • To explore targeting nonapoptotic CD95 signaling for cancer treatment.

Main Methods:

  • Literature review of studies on CD95 signaling in cancer.
  • Analysis of research on CD95's apoptotic and nonapoptotic functions.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Experiment Videos

Last Updated: May 12, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

  • Examination of clinical strategies involving CD95 manipulation.

    • Main Results:

    • CD95 exhibits contradictory roles in cancer, capable of both inhibiting and promoting tumor growth.
    • Nonapoptotic CD95 signaling pathways are implicated in enhancing tumorigenesis.
    • The dual nature of CD95 challenges its use as a simple 'tumor killer'.

    Conclusions:

    • Targeting the nonapoptotic signaling branch of CD95 presents a novel therapeutic strategy.
    • Understanding CD95's complex roles is crucial for developing effective cancer treatments.
    • Future clinical studies should focus on modulating specific CD95 signaling pathways.